Disease Pad Articles & Analysis: Older
4 articles found
Start-up Alucent Biomedical is using a light-activated molecule, delivered via a balloon catheter, to create a natural vascular scaffold in diseased peripheral vessels, with the aim of providing a long-lasting treatment option that maintains patency while leaving nothing behind in the vessel. Alucent Biomedical Inc. is rethinking peripheral artery disease (PAD) treatment with a novel natural ...
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire Vesper Medical Inc., a US-based medical technology company that develops minimally-invasive peripheral vascular devices. Vesper Medical will further expand Philips’ portfolio of diagnostic and therapeutic devices ...
Abstract Background. As the most advanced stage of peripheral arterial disease (PAD), chronic limb-threatening ischemia (CLTI) is associated with a high risk of lower-limb loss and mortality. Percutaneous deep vein arterialization (pDVA) is a promising new treatment alternative for CLTI patients who cannot be treated with conventional revascularization techniques. Our study objective was to ...
As part of our ongoing Vascular Innovation Series in conjunction with The Way to My Heart, journalist Kym McNicholas interviewed Alucent Biomedical CEO, Dr. Myles Greenberg. Treatment for vascular blockages is getting a much-needed innovation makeover. Alucent’s first area of focus is one the most debilitating vascular diseases –peripheral artery disease, plaque build-up in mainly ...